Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).
Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.
Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).
Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).
The review found no eligible studies for this question.
Low‐molecular‐weight heparin leads to lower symptomatic VTE compared with no thromboprophylaxis (high certainty).
Low molecular weight heparin may leads to lower symptomatic venous thromboembolism compared with no prophylaxis or placebo (low certainty).
It is very uncertain whether low‐molecular‐weight heparin changes asymptomatic DVT: compared with no prophylaxis (very low certainty).
Low‐molecular‐weight heparins or heparinoids showed no clear difference in symptomatic intracranial haemorrhage/haemorrhagic transformation of… compared with unfractionated heparin (low certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with placebo (moderate certainty).
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic VTE compared with placebo (high certainty).
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).
Low‐molecular‐weight heparin showed no clear difference in symptomatic DVT: assessed by presence of symptoms and confirmed by a… compared with no prophylaxis (low certainty).
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
Low‐molecular‐weight heparin (LMWH) probably leads to lower symptomatic catheter‐related thrombosis (up to 3 months) compared with no LMWH (moderate certainty).
Does low molecular weight heparin prevent central venous… showed no clear difference in symptomatic CVC‐related thrombosis ( compared with control (low certainty).
Does low molecular weight heparin prevent central venous… showed no clear difference in asymptomatic CVC‐related thrombosis ( compared with control (low certainty).
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with vitamin K antagonist (VKA) (very low certainty).
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no LMWH (very low certainty).